UY26265A1 - Compuestos calciolíticos - Google Patents

Compuestos calciolíticos

Info

Publication number
UY26265A1
UY26265A1 UY26265A UY26265A UY26265A1 UY 26265 A1 UY26265 A1 UY 26265A1 UY 26265 A UY26265 A UY 26265A UY 26265 A UY26265 A UY 26265A UY 26265 A1 UY26265 A1 UY 26265A1
Authority
UY
Uruguay
Prior art keywords
calciolytic
compounds
disorders
new methods
bone diseases
Prior art date
Application number
UY26265A
Other languages
English (en)
Inventor
Maxine Gowen Larry Suva Stroup
Original Assignee
Smithkline Beecham Corp Y Nps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp Y Nps filed Critical Smithkline Beecham Corp Y Nps
Publication of UY26265A1 publication Critical patent/UY26265A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan nuevos métodos para tratar enfermedades o trastornos de los huesos.
UY26265A 1999-07-31 2000-07-31 Compuestos calciolíticos UY26265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14677899P 1999-07-31 1999-07-31

Publications (1)

Publication Number Publication Date
UY26265A1 true UY26265A1 (es) 2001-03-16

Family

ID=22518969

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26265A UY26265A1 (es) 1999-07-31 2000-07-31 Compuestos calciolíticos

Country Status (21)

Country Link
EP (1) EP1200076A4 (es)
JP (1) JP2003505502A (es)
KR (1) KR20020016928A (es)
CN (1) CN1367687A (es)
AU (1) AU764716B2 (es)
BR (1) BR0012921A (es)
CA (1) CA2380081A1 (es)
CO (1) CO5180628A1 (es)
CZ (1) CZ2002360A3 (es)
EC (1) ECSP003590A (es)
HK (1) HK1046238A1 (es)
HU (1) HUP0202167A3 (es)
IL (1) IL147875A0 (es)
MX (1) MXPA02001204A (es)
NO (1) NO20020466L (es)
PE (1) PE20010459A1 (es)
PL (1) PL353318A1 (es)
TR (1) TR200200278T2 (es)
UY (1) UY26265A1 (es)
WO (1) WO2001008673A1 (es)
ZA (1) ZA200200784B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
UY30801A1 (es) * 2006-12-18 2008-07-03 Smithkline Beecham Corp Compuestos calciliticos
WO2013098588A1 (en) * 2011-12-27 2013-07-04 Ubaldo Armato Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN108420814A (zh) * 2017-02-15 2018-08-21 四川大学 一种nps-2143用于抗菌的新用途
CN116173187B (zh) * 2023-03-14 2024-05-10 哈尔滨医科大学 降钙素在制备防治支架内再狭窄药物中的应用、药物涂层支架及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU726659B2 (en) * 1996-04-09 2000-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
MY121054A (en) * 1998-04-08 2005-12-30 Smithkline Beecham Corp Calcilytic compounds as calcium receptor antagonists.
AR014975A1 (es) * 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento

Also Published As

Publication number Publication date
AU764716B2 (en) 2003-08-28
IL147875A0 (en) 2002-08-14
PL353318A1 (en) 2003-11-17
HUP0202167A3 (en) 2006-07-28
CA2380081A1 (en) 2001-02-08
EP1200076A1 (en) 2002-05-02
KR20020016928A (ko) 2002-03-06
CN1367687A (zh) 2002-09-04
ZA200200784B (en) 2003-01-29
CO5180628A1 (es) 2002-07-30
JP2003505502A (ja) 2003-02-12
BR0012921A (pt) 2002-06-18
MXPA02001204A (es) 2004-05-21
NO20020466D0 (no) 2002-01-29
PE20010459A1 (es) 2001-06-11
NO20020466L (no) 2002-03-20
EP1200076A4 (en) 2005-02-09
AU6504100A (en) 2001-02-19
HUP0202167A2 (en) 2002-10-28
CZ2002360A3 (cs) 2002-10-16
ECSP003590A (es) 2002-02-25
WO2001008673A1 (en) 2001-02-08
TR200200278T2 (tr) 2002-06-21
HK1046238A1 (zh) 2003-01-03

Similar Documents

Publication Publication Date Title
DK2052714T3 (da) Topisk gel-fremføringssystem til behandling af hudlidelser
BR9911781B1 (pt) iluminador para terapia fotodinámica.
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
PT967214E (pt) Formulacoes intranasais para o tratamento de desordens sexuais
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
ATE299854T1 (de) Chinonverbindungen zur behandlung von krankheiten
PT1206436E (pt) Retinoides para o tratamento de enfisema
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
UY26265A1 (es) Compuestos calciolíticos
EE200300366A (et) Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil
ATE265455T1 (de) Tetrahydropyridoverbindungen
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
PT983275E (pt) Novos derivados do triptolido vantajosos para o tratamento de doencas autoimunes
SE9801494D0 (sv) Novel use
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
YU60101A (sh) Derivati rezorcinola
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
PT1170591E (pt) Metodos para identificar combinacoes de identidades como agentes terapeuticos
DE60138371D1 (de) PROSTAGLANDINE zur Behandlung von Lichtstrahlung erzeugten Augenerkrankungen wie Photoretinitis

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20101025